Correlation Between 23Andme Holding and Actinium Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both 23Andme Holding and Actinium Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 23Andme Holding and Actinium Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between 23Andme Holding Co and Actinium Pharmaceuticals, you can compare the effects of market volatilities on 23Andme Holding and Actinium Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 23Andme Holding with a short position of Actinium Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of 23Andme Holding and Actinium Pharmaceuticals.

Diversification Opportunities for 23Andme Holding and Actinium Pharmaceuticals

0.56
  Correlation Coefficient

Very weak diversification

The 3 months correlation between 23Andme and Actinium is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and Actinium Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Actinium Pharmaceuticals and 23Andme Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 23Andme Holding Co are associated (or correlated) with Actinium Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Actinium Pharmaceuticals has no effect on the direction of 23Andme Holding i.e., 23Andme Holding and Actinium Pharmaceuticals go up and down completely randomly.

Pair Corralation between 23Andme Holding and Actinium Pharmaceuticals

Allowing for the 90-day total investment horizon 23Andme Holding Co is expected to under-perform the Actinium Pharmaceuticals. In addition to that, 23Andme Holding is 1.61 times more volatile than Actinium Pharmaceuticals. It trades about -0.2 of its total potential returns per unit of risk. Actinium Pharmaceuticals is currently generating about -0.12 per unit of volatility. If you would invest  168.00  in Actinium Pharmaceuticals on August 26, 2024 and sell it today you would lose (23.00) from holding Actinium Pharmaceuticals or give up 13.69% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

23Andme Holding Co  vs.  Actinium Pharmaceuticals

 Performance 
       Timeline  
23Andme Holding 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days 23Andme Holding Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Actinium Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Actinium Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

23Andme Holding and Actinium Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with 23Andme Holding and Actinium Pharmaceuticals

The main advantage of trading using opposite 23Andme Holding and Actinium Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 23Andme Holding position performs unexpectedly, Actinium Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will offset losses from the drop in Actinium Pharmaceuticals' long position.
The idea behind 23Andme Holding Co and Actinium Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Complementary Tools

Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance